Cite
HARVARD Citation
McKay, R. et al. (2016). A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor‐targeted therapies. Cancer. 122 (15), pp. 2389-2398. [Online].